1. γδT17/γδTreg cell subsets: a new paradigm for asthma treatment
- Author
-
Tian-Xia Huang, Cai-Cheng Qin, Chao-Mian Yang, and Yi-En Yao
- Subjects
Pulmonary and Respiratory Medicine ,business.industry ,Asthma treatment ,Disease ,medicine.disease ,T-Lymphocytes, Regulatory ,Pathophysiology ,Asthma ,respiratory tract diseases ,Pathogenesis ,Immune system ,immune system diseases ,Pediatrics, Perinatology and Child Health ,T cell subset ,Immunology ,medicine ,Immunology and Allergy ,Humans ,Th17 Cells ,Disease Susceptibility ,Airway ,business ,Lung - Abstract
Bronchial asthma (abbreviated as asthma), is a heterogeneous disease characterized by chronic airway inflammation and airway hyperresponsiveness. The main characteristics of asthma include variable reversible airflow limitation and airway remodeling. The pathogenesis of asthma is still unclear. Th1/Th2 imbalance, Th1 deficiency and Th2 hyperfunction are classic pathophysiological mechanisms of asthma. Some studies have shown that the imbalance of the Th1/Th2 cellular immune model and Th17/Treg imbalance play a key role in the occurrence and development of asthma; however, these imbalances do not fully explain the disease. In recent years, studies have shown that γδT and γδT17 cells are involved in the pathogenesis of asthma. γδTreg has a potential immunosuppressive function, but its regulatory mechanisms have not been fully elucidated. In this paper, we reviewed the role of γδT17/γδTreg cells in bronchial asthma, including the mechanisms of their development and activation. Here we propose that γδT17/Treg cell subsets contribute to the occurrence and development of asthma, constituting a novel potential target for asthma treatment.
- Published
- 2021